Pancreatic β‐cell turnover in health and disease
Diabetes, Obesity and Metabolism · 2026-01 · 28 (1) · 27-49
DOI: 10.1111/dom.70191 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 29.10.2025. Verfasst von Yasmine Alcibahy und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Royal College of Surgeons in Ireland, Bahrain, Adliya, Bahrain. Hauptthemen laut MEDLINE: Insulin-Secreting Cells, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 259 Literaturangaben.
Abstract (Originalsprache)
Pancreatic β‐cell mass is a principal determinant of glucose homeostasis, and its loss or dysfunction underlies both type 1 and type 2 diabetes. Restoring functional β‐cell mass whether through replication of existing β‐cells, neogenesis from alternative cellular sources, or protection of stressed cells remains a central therapeutic goal. In this review article, we synthesize evidence from rodent and human studies under normal physiology to highlight how β‐cell mass is established, maintained, and adapted. We emphasize the steep decline in proliferative capacity after early life, the long lifespan of adult β‐cells, and the limited, context‐dependent adaptations observed in obesity, pregnancy, insulin resistance, and impaired glucose tolerance. Beyond apoptosis, β‐cell dedifferentiation has emerged as a key mechanism of functional decline, whereby mature β‐cells lose identity, revert to a progenitor‐like state, and contribute to reduced insulin output. We also examine cell‐intrinsic brakes on proliferation, the trophic roles of incretins and growth factors, and the debated contribution of neogenesis and transdifferentiation from ductal, acinar, or non‐β endocrine lineages. Advances in β‐cell mass quantification, including glucagon‐like peptide‐1 (GLP‐1) receptor‐targeted imaging, are discussed alongside methodological challenges in human tissue studies. Finally, we review therapeutic avenues such as GLP‐1 receptor agonists (GLP‐1RAs) that mitigate ER and oxidative stress, restore autophagy, and preserve functional mass. Together, these insights frame testable strategies to prevent β‐cell failure and guide diabetes therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Royal College of Surgeons in Ireland, Bahrain, Adliya, Bahrain.
- School of Postgraduate Studies and Research, Royal College of Surgeons in Ireland, Bahrain, Adliya, Bahrain.
ORCID-Profile: Abu Saleh Md Moin
Zitieren
APA
Alcibahy, Y., Darwish, R., Butler, A. E., & Moin, A. S. M. (2026). Pancreatic β‐cell turnover in health and disease. Diabetes, Obesity and Metabolism, 28(1), 27-49. https://doi.org/10.1111/dom.70191
Vancouver
Alcibahy Y, Darwish R, Butler AE, Moin ASM. Pancreatic β‐cell turnover in health and disease. Diabetes, Obesity and Metabolism. 2026;28(1):27-49. doi:10.1111/dom.70191
BibTeX
@article{Alcibahy2026,
author = {Alcibahy, Yasmine and Darwish, Radwan and Butler, Alexandra E and Moin, Abu Saleh Md},
title = {Pancreatic β‐cell turnover in health and disease},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {1},
pages = {27--49},
doi = {10.1111/dom.70191}
}
EUVIMED